S F Stone1, P Price, M A French. 1. Department of Clinical Immunology and Biochemical Genetics, Royal Perth Hospital and School of Surgery and Pathology, University of Western Australia, Perth, Australia. sfstone@graduate.uwa.edu.au
Abstract
OBJECTIVES: Current guidelines recommend commencing highly active antiretroviral therapy (HAART) in HIV-infected patients when CD4 T-cell counts reach 350 cells/microL. However, late-presenting HIV-infected patients with CD4 T-cell counts<50 cells/microL are still common. The ability of long-term HAART to normalize immune dysregulation in severely immunodeficient HIV-infected patients remains unclear. Here we address indices of immune dysregulation in previously severely immunocompromised HIV-infected patients treated with long-term HAART who had achieved increased CD4 T-cell counts and complete suppression of HIV viraemia. METHODS: We examined expression of CD28, cytotoxic T-lymphocyte antigen-4 (CTLA-4) and intracellular perforin by CD4 and CD8 lymphocytes from 25 highly selected HIV-infected patients [nadir CD4 T-cell counts <50 cells/microL, >4 years on HAART and >6 months of complete viral suppression (<50 HIV-1 RNA copies/mL)] and 18 HIV-seronegative age- and sex-matched controls. RESULTS: HIV-infected patients had lower percentages of CD28-expressing CD4 lymphocytes and higher percentages of CTLA-4-expressing CD4 lymphocytes than controls. The percentage of CTLA-4-expressing CD4 lymphocytes correlated inversely with that of CD28-expressing CD4 lymphocytes. The proportion of CD4 lymphocytes expressing perforin was generally low. However, more HIV-infected patients than controls had >1% of CD4 lymphocytes expressing perforin [11 of 25 (44%) vs. one of 18 (5.5%)]. The percentage of CD8 lymphocytes expressing perforin did not differ between HIV-infected patients and controls. Amongst HIV-infected patients, the percentage of perforin-expressing CD8 lymphocytes correlated inversely with nadir but not current CD4 T-cell count. CONCLUSIONS: Expression of CD28, CTLA-4 and perforin by CD4 lymphocytes remain dysregulated in HIV-infected patients with previous severe immunodeficiency, despite increased CD4 T-cell counts and control of HIV viraemia by HAART.
OBJECTIVES: Current guidelines recommend commencing highly active antiretroviral therapy (HAART) in HIV-infectedpatients when CD4 T-cell counts reach 350 cells/microL. However, late-presenting HIV-infectedpatients with CD4 T-cell counts<50 cells/microL are still common. The ability of long-term HAART to normalize immune dysregulation in severely immunodeficient HIV-infectedpatients remains unclear. Here we address indices of immune dysregulation in previously severely immunocompromised HIV-infectedpatients treated with long-term HAART who had achieved increased CD4 T-cell counts and complete suppression of HIV viraemia. METHODS: We examined expression of CD28, cytotoxic T-lymphocyte antigen-4 (CTLA-4) and intracellular perforin by CD4 and CD8 lymphocytes from 25 highly selected HIV-infectedpatients [nadir CD4 T-cell counts <50 cells/microL, >4 years on HAART and >6 months of complete viral suppression (<50 HIV-1 RNA copies/mL)] and 18 HIV-seronegative age- and sex-matched controls. RESULTS:HIV-infectedpatients had lower percentages of CD28-expressing CD4 lymphocytes and higher percentages of CTLA-4-expressing CD4 lymphocytes than controls. The percentage of CTLA-4-expressing CD4 lymphocytes correlated inversely with that of CD28-expressing CD4 lymphocytes. The proportion of CD4 lymphocytes expressing perforin was generally low. However, more HIV-infectedpatients than controls had >1% of CD4 lymphocytes expressing perforin [11 of 25 (44%) vs. one of 18 (5.5%)]. The percentage of CD8 lymphocytes expressing perforin did not differ between HIV-infectedpatients and controls. Amongst HIV-infectedpatients, the percentage of perforin-expressing CD8 lymphocytes correlated inversely with nadir but not current CD4 T-cell count. CONCLUSIONS: Expression of CD28, CTLA-4 and perforin by CD4 lymphocytes remain dysregulated in HIV-infectedpatients with previous severe immunodeficiency, despite increased CD4 T-cell counts and control of HIV viraemia by HAART.
Authors: Risa M Hoffman; Beth D Jamieson; Ronald J Bosch; Judith Currier; Christina M R Kitchen; Ingrid Schmid; Yuda Zhu; Kara Bennett; Ronald Mitsuyasu Journal: J Clin Immunol Date: 2011-06-04 Impact factor: 8.317
Authors: Ramy El-Diwany; Florian P Breitwieser; Mary Soliman; Alyza M Skaist; Geetha Srikrishna; Joel N Blankson; Stuart C Ray; Sarah J Wheelan; David L Thomas; Ashwin Balagopal Journal: AIDS Date: 2017-06-19 Impact factor: 4.177
Authors: John J Zaunders; Susanna Ip; Mee Ling Munier; Daniel E Kaufmann; Kazuo Suzuki; Choechoe Brereton; Sarah C Sasson; Nabila Seddiki; Kersten Koelsch; Alan Landay; Pat Grey; Robert Finlayson; John Kaldor; Eric S Rosenberg; Bruce D Walker; Barbara Fazekas de St Groth; David A Cooper; Anthony D Kelleher Journal: J Virol Date: 2006-10 Impact factor: 5.103
Authors: Afework Kassu; Michelle D'Souza; Brian P O'Connor; Elizabeth Kelly-McKnight; Ramesh Akkina; Andrew P Fontenot; Brent E Palmer Journal: Clin Immunol Date: 2009-04-29 Impact factor: 3.969
Authors: Alexandra M Miggelbrink; Joshua D Jackson; Selena J Lorrey; Ethan S Srinivasan; Jessica Waibl-Polania; Daniel S Wilkinson; Peter E Fecci Journal: Clin Cancer Res Date: 2021-06-14 Impact factor: 12.531